New Drug Delivery System Targets Diseases at a Genetic Level

News   Dec 06, 2017 | Original story from University of Connecticut

 
New Drug Delivery System Targets Diseases at a Genetic Level

Enzyme-triggered degradation of a drug loaded peptide-crosslinked nucleic acid nanocapsule. First a peptide is crosslinked at the nanoparticle surface (1), then an enzyme recognizes the peptide crosslinker (2), and finally the enzyme cleavage leads to the release of the drug and any intact DNA (3). Credit: (Artwork by Joseph Luciani/UConn)

 
 
 

RELATED ARTICLES

Tailor-made Protein Fights Several Species of Bacteria

News

As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.

READ MORE

Anti-stress Compound Reduces Obesity and Diabetes

News

Scientists could prove that a stress protein found in muscle has a diabetes promoting effect. This finding could pave the way to a completely new treatment approach.

READ MORE

First Successful Gene Therapy Trial Reported for People with Hemophilia A

News

Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Cell Science Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE